（原标题：【券商聚焦】中泰证券首予金斯瑞生物科技(01548)“买入”评级 指其细胞治疗产品将迎收获）金吾财讯|中泰证券发布研报指，金斯瑞生物科技(01548.HK)作为全球领先的一站式CRDMO平台，细胞治疗产品逐步收获，有望迎来系统性重估。该行首次覆盖给予“买入”评级。 报告指出，公司四大板块协同发展：生命科学服务业务全球市占率20-30%，蛋白合成成为第二增长曲线；蓬勃生物2025H1收入...
Source Link（原标题：【券商聚焦】中泰证券首予金斯瑞生物科技(01548)“买入”评级 指其细胞治疗产品将迎收获）金吾财讯|中泰证券发布研报指，金斯瑞生物科技(01548.HK)作为全球领先的一站式CRDMO平台，细胞治疗产品逐步收获，有望迎来系统性重估。该行首次覆盖给予“买入”评级。 报告指出，公司四大板块协同发展：生命科学服务业务全球市占率20-30%，蛋白合成成为第二增长曲线；蓬勃生物2025H1收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.